July 1, 2022
AbbVie said on June 30 that it filed an additional indication for its IL-23 inhibitor Skyrizi (Risankizumab) in Japan for the treatment of adults with palmoplantar pustulosis (PPP) inadequately controlled with existing therapies. The move is based on the results...read more